Halda Therapeutics is a biotechnology company, founded by Professor Craig Crews from Yale University, that has developed a proprietary RIPTAC™ (Regulated Induced Proximity Targeting Chimeras) modality that works by a novel 'hold and kill' mechanism for the precision treatment of cancer. The novel mechanism of action of RIPTAC therapeutics is uniquely designed to address cancer's ability to evolve bypass mechanisms of resistance, a common limitation of today's precision oncology medicines. Our lead RIPTAC programs are in development for major solid tumor types, prostate cancer and breast cancer, with additional RIPTAC therapeutic programs in our pipeline to treat unmet medical needs in cancer. The company will initiate its Phase 1 trial in metastatic, castration-resistant prostate cancer (mCRPC) in 2025. Halda is led by a leadership team with deep expertise in bifunctional drug discovery, platform innovation and clinical development, and is located in New Haven, CT.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/12/24 | $126,000,000 | Series B Extension |
Access Biotechnology Boxer Capital Canaan Partners Connecticut Innovations Deep Track Capital Elm Street Ventures Frazier Life Sciences RA Capital Management Taiho Ventures Vida Ventures | undisclosed |
